Rathbones Group PLC Sells 4,200 Shares of Astrazeneca Plc $AZN

Rathbones Group PLC lessened its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 35.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,537 shares of the company’s stock after selling 4,200 shares during the period. Rathbones Group PLC’s holdings in Astrazeneca were worth $1,323,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca during the 3rd quarter worth about $25,000. Bangor Savings Bank lifted its position in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca during the 4th quarter worth about $30,000. Rakuten Investment Management Inc. acquired a new position in shares of Astrazeneca during the 3rd quarter worth about $31,000. Finally, YANKCOM Partnership acquired a new position in shares of Astrazeneca during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AZN shares. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday. Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings started coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Trading Down 1.3%

Shares of AZN opened at $187.24 on Friday. The stock has a market cap of $290.39 billion, a PE ratio of 28.11, a PEG ratio of 1.56 and a beta of 0.26. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The stock has a 50 day simple moving average of $191.66 and a 200-day simple moving average of $182.86. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, sell-side analysts predict that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.